New York Angels invested $625,000 in CardiaCare, a medical device company developing a non-invasive therapy for atrial fibrillation, reflecting confidence in the growing healthcare technology market.

Target Company Overview

CardiaCare is an innovative medical device company that is developing the first-ever non-invasive neuromodulation therapy specifically designed for atrial fibrillation (AFib). The therapy is delivered through a convenient and discreet wearable device. By coupling proprietary neuromodulation technology with advanced AI-enabled cardiac rhythm monitoring, CardiaCare is positioned to provide remote and personalized patient care, revolutionizing the way AFib is managed.

With insights gathered from interviews with prominent electrophysiologists, New York Angels (NYA) members were inspired to proceed with their investment in CardiaCare. This reflects a strong belief in the company's potential to address a significant healthcare need with its cutting-edge technology.

Industry Overview in the U.S.

The healthcare technology sector in the United States has been experiencing rapid growth, driven by advancements in telemedicine, wearable devices, and artificial intelligence. The increasing demand for remote health monitoring and treatment op